Literature DB >> 18389388

Mutation spectrum in HNPCC in the Israeli population.

Yael Goldberg1, Rinnat M Porat, Inbal Kedar, Chen Shochat, Michal Sagi, Avital Eilat, Suzan Mendelson, Tamar Hamburger, Aviram Nissan, Ayala Hubert, Luna Kadouri, Eli Pikarski, Israela Lerer, Dvorah Abeliovich, Dani Bercovich, Tamar Peretz.   

Abstract

Hereditary non-polyposis colon cancer is caused by mutations in DNA mismatch repair genes. The mutation spectrum in the Israeli population is poorly documented except for the c.1906G>C Ashkenazi founder mutation in the hMSH2 gene. To report our experience in HNPCC screening, the mutations detected and the clinical features among a cohort of Israeli patients. Diagnostic work-up was done in a multi-step process guided by clinical and ethnic information. Tumors of suspected patients were tested for microsatellite instability and immunohistochemistry. Based on tumor analyses, we proceeded to mutation screening by DHPLC followed by sequence analysis and multiplex ligase dependent probe amplification. Ashkenazi Jews were first tested for the c.1906G>C founder mutation. Of the 240 families, 24, including Arabs and Jews from different ethnic origins, were tested positive. All tumors that lost expression of mismatch repair proteins also showed microsatellite instability. There was evidence for involvement of hMSH2 (15) hMLH1 (6) and hMSH6 (3) genes. Mutations were identified in 17/24 (71%) patients: 6 Ashkenazi families harbored the c.1906G>C mutation. Eleven other mutations (2 nonsense, 3 splice site and 6 small deletions) were detected. Three of the mutations are novel. No gross deletions or insertions were detected. This is the first report that characterizes the profile of HNPCC in a cohort of patients in Israel. Tumor testing indicated that the 3 main MMR genes are involved, and that mutation spectrum is broad.

Entities:  

Mesh:

Year:  2008        PMID: 18389388     DOI: 10.1007/s10689-008-9191-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  Microsatellite instability.

Authors:  Albert de la Chapelle
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

2.  MSH2 genomic deletions are a frequent cause of HNPCC.

Authors:  J Wijnen; H van der Klift; H Vasen; P M Khan; F Menko; C Tops; H Meijers Heijboer; D Lindhout; P Møller; R Fodde
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

3.  Novel germline mutation (300-305delAGTTGA) in the human MSH2 gene in hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  S Glasl; L Papatheodorou; G Baretton; C Jung; M Gross
Journal:  Hum Mutat       Date:  2000-07       Impact factor: 4.878

4.  Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.

Authors:  Jian Qiu Sheng; Tsun Leung Chan; Yee Wai Chan; Ji Sheng Huang; Ji Gui Chen; Ming Zhi Zhang; Xiu Lan Guo; Hong Mu; Annie Sy Chan; Shi Rong Li; Siu Tsan Yuen; Suet Yi Leung
Journal:  Chin J Dig Dis       Date:  2006

5.  No MSH6 germline mutations in breast cancer families with colorectal and/or endometrial cancer.

Authors:  P Vahteristo; S Ojala; A Tamminen; J Tommiska; H Sammalkorpi; S Kiuru-Kuhlefelt; H Eerola; L A Aaltonen; K Aittomäki; H Nevanlinna
Journal:  J Med Genet       Date:  2005-04       Impact factor: 6.318

6.  The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

Authors:  W D Foulkes; I Thiffault; S B Gruber; M Horwitz; N Hamel; C Lee; J Shia; A Markowitz; A Figer; E Friedman; D Farber; C M T Greenwood; J D Bonner; K Nafa; T Walsh; V Marcus; L Tomsho; J Gebert; F A Macrae; C L Gaff; B Bressac-De Paillerets; P K Gregersen; J N Weitzel; P H Gordon; E MacNamara; M-C King; H Hampel; A De La Chapelle; J Boyd; K Offit; G Rennert; G Chong; N A Ellis
Journal:  Am J Hum Genet       Date:  2002-11-26       Impact factor: 11.025

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

9.  Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer.

Authors:  M Fujita; T Enomoto; K Yoshino; T Nomura; G S Buzard; M Inoue; Y Okudaira
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

10.  MSH6 germline mutations are rare in colorectal cancer families.

Authors:  Paolo Peterlongo; Khedoudja Nafa; Gabriel S Lerman; Emily Glogowski; Jinru Shia; Tian Z Ye; Arnold J Markowitz; José G Guillem; Prema Kolachana; Jeffrey A Boyd; Kenneth Offit; Nathan A Ellis
Journal:  Int J Cancer       Date:  2003-11-20       Impact factor: 7.396

View more
  10 in total

1.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

Review 2.  Genetic counseling services and training of genetic counselors in Israel: an overview.

Authors:  Michal Sagi; Wendy R Uhlmann
Journal:  J Genet Couns       Date:  2013-02-24       Impact factor: 2.537

3.  Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases.

Authors:  Jun-Xiao Zhang; Lei Fu; Richarda M de Voer; Marc-Manuel Hahn; Peng Jin; Chen-Xi Lv; Eugène Tp Verwiel; Marjolijn Jl Ligtenberg; Nicoline Hoogerbrugge; Roland P Kuiper; Jian-Qiu Sheng; Ad Geurts van Kessel
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

4.  A study on MSH2 and MLH1 mutations in hereditary nonpolyposis colorectal cancer families from the Basque Country, describing four new germline mutations.

Authors:  Cristina Martínez-Bouzas; Elena Beristain; Enrique Ojembarrena; Jose Errasti; Karmele Mujika; Noelia Viguera; Maria Isabel Tejada
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

5.  Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.

Authors:  Helen Toledano; Yael Goldberg; Inbal Kedar-Barnes; Hagit Baris; Rinnat M Porat; Chen Shochat; Dani Bercovich; Eli Pikarsky; Israela Lerer; Isaac Yaniv; Dvorah Abeliovich; Tamar Peretz
Journal:  Fam Cancer       Date:  2008-12-20       Impact factor: 2.375

6.  An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Daliah Galinsky; Tamar Hamburger; Ayala Hubert; Hana Strul; Revital Kariiv; Liat Ben-Avi; Moran Savion; Eli Pikarsky; Dvorah Abeliovich; Dani Bercovich; Israela Lerer; Tamar Peretz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

7.  Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.

Authors:  Ido Laish; Eitan Friedman; Gili Levi-Reznick; Inbal Kedar; Lior Katz; Zohar Levi; Naama Halpern; Shani Parnasa; Aasem Abu-Shatya; Elizabeth Half; Yael Goldberg
Journal:  Breast Cancer Res Treat       Date:  2021-06-04       Impact factor: 4.872

8.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.

Authors:  T Yokota; T Ura; N Shibata; D Takahari; K Shitara; M Nomura; C Kondo; A Mizota; S Utsunomiya; K Muro; Y Yatabe
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

Review 9.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

10.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.